Ionis Pharmaceuticals, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Ionis Pharmaceuticals, Inc. (IONS) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$381.18 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-26
- Ionis Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$381.18M.
- Ionis Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$460.71M.
- Ionis Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$334.71M.
- Ionis Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$258.49M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$381.18M 10-K · filed 2026-02-26 | |
| 2024-12-31 | -$460.71M 10-K · filed 2026-02-26 | |
| 2023-12-31 | -$334.71M 10-K · filed 2026-02-26 | |
| 2022-12-31 | -$258.49M 10-K · filed 2025-02-19 | |
| 2021-12-31 | -$29.97M 10-K · filed 2024-02-21 | |
| 2020-12-31 | -$137.22M 10-K · filed 2023-02-22 | -$172.70M 10-K · filed 2021-02-24 |
| 2019-12-31 | $336.28M 10-K · filed 2022-02-25 | $344.28M 10-K · filed 2020-03-02 |
| 2018-12-31 | -$69.58M 10-K · filed 2021-02-24 | |
| 2017-12-31 | -$5.29M 10-K · filed 2020-03-02 | -$11.80M 10-K · filed 2018-02-28 |
| 2016-12-31 | -$57.47M 10-K · filed 2019-03-01 | -$83.62M 10-K · filed 2018-02-28 |
| 2015-12-31 | -$87.91M 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |